Cargando…

Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-small Cell Lung Cancer Patients Treated with Immunotherapy

BACKGROUND: Uncommon response during immunotherapy is a new challenging issue in oncology practice. Recently, new criteria for evaluation of response to immunotherapy immune response evaluation criteria in solid tumors (iRECIST) were accepted. According to iRECIST, worsening of performance status (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vrankar, Martina, Unk, Mojca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287173/ https://www.ncbi.nlm.nih.gov/pubmed/30367809 http://dx.doi.org/10.2478/raon-2018-0037

Ejemplares similares

[(18)F]FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
por: Valentinuzzi, Damijan, et al.
Publicado: (2020)

Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
por: Song, Peng, et al.
Publicado: (2019)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
por: Choi, Hyun Chang, et al.
Publicado: (2015)

Long-term Survival of Locally Advanced Stage III Non-small Cell Lung Cancer Patients Treated with Chemoradiotherapy and Perspectives for The Treatment with Immunotherapy
por: Vrankar, Martina, et al.
Publicado: (2018)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer
por: Suyanto, Suyanto, et al.
Publicado: (2019)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

Response criteria in solid tumors (PERCIST/RECIST) and SUV(max) in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
por: Pierson, Cory, et al.
Publicado: (2018)

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
por: Won, Sang Eun, et al.
Publicado: (2020)

Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report
por: Gonugunta, Amrit S., et al.
Publicado: (2022)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
por: Ades, Felipe, et al.
Publicado: (2015)

Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study
por: Toffart, Anne-Claire, et al.
Publicado: (2014)

Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
por: Vrankar, Martina, et al.
Publicado: (2020)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Consolidation Radiotherapy for Patients with Extended Disease Small Cell Lung Cancer in a Single Tertiary Institution: Impact of Dose and Perspectives in the Era of Immunotherapy
por: Stanic, Karmen, et al.
Publicado: (2020)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
por: Lee, Jae Seung, et al.
Publicado: (2020)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
por: Zhu, Wanshan, et al.
Publicado: (2023)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
por: Kato, Ryoji, et al.
Publicado: (2017)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
por: Xu, Yuan, et al.
Publicado: (2023)

Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
por: Mönch, Sebastian, et al.
Publicado: (2023)

Pseudoprogression in lung cancer: a case report
por: Meoni, Giulia, et al.
Publicado: (2020)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

F-18 Fluciclovine PET-CT Findings and Pseudoprogression on Immunotherapy
por: Poindexter, Bradley C, et al.
Publicado: (2022)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA
por: Le Rhun, Emilie, et al.
Publicado: (2019)

Incorporation of EGFR Mutation Status into M Descriptor of New TNM Classification Influences Survival Curves in Non-small Cell Lung Cancer Patients
por: Stanic, Karmen, et al.
Publicado: (2019)

Well‐controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report
por: Liu, Guihong, et al.
Publicado: (2018)

Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?
por: Gupta, Manoj, et al.
Publicado: (2022)

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
por: Kim, Hong Deok, et al.
Publicado: (2019)

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study
por: Lucidarme, Olivier, et al.
Publicado: (2019)

Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?
por: Patil, V., et al.
Publicado: (2013)

Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
por: Ljubicic, Lidija, et al.
Publicado: (2023)

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
por: Jia, Wenxiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_29ahl6ijlr3suuelhgjsor3lbd